Skip to main content
Caplight Logo









Expedition Therapeutics

Expedition Therapeutics

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://expeditiontx.com/

Last Round

Series B

Aug 5, 2026

Est. Valuation

$650M

Total Funding Raised

$280M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Expedition Therapeutics is a biotechnology company developing novel therapies for serious inflammatory and respiratory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverytherapeutic candidatesbiotechclinical trialssmall-molecule inhibitorDPP1 inhibitorrespiratory diseaseCOPD treatmentdrug developmentbiopharmapreclinical developmentlicensing agreementmilestone paymentspharma pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Expedition Therapeutics Comparables

Compare Expedition Therapeutics with similar companies based on industry and business-model similarity.

Expedition Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Coultreon Biopharma
74%
GSK plc
72%
Slate Medicines
71%

Expedition Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BAug 5, 2026
Series AOct 9, 2025

Key People

Founding team and executive leadership

Yi Larson

President and CEO

Executive Team

Expedition Therapeutics Investors

Notable investors and investment history

Expedition Therapeutics investors
InvestorRounds
Balyasny Asset Management L.P.Series A, Series B
RA Capital ManagementSeries B
Lake Bleu CapitalSeries A
ForbionSeries A, Series B
Logos CapitalSeries A, Series B
Novo HoldingsSeries B, Series A
BVF Partners L.P.Series A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 3, 2026

    Grew 21% QoQ from 14 to 17 employees.

  • Aug 22, 2026

    Monthly visitors increased 47% MoM, reaching 2.3K.

Recent news

Latest coverage and updates

  • hiresAug 5, 2026

    Expedition Therapeutics Inc. hired Brett Zbar as Board of Directors on Aug 6th '26.

  • is_developingAug 5, 2026

    Expedition Therapeutics Inc. is developing novel oral small molecule therapies for inflammatory and respiratory diseases on Aug 5th '26.

  • receives_financingAug 5, 2026

    Expedition Therapeutics Inc. received financing of $115M in Series B on Aug 5th '26.

Expedition Therapeutics Filings

Explore SEC and related filing metadata, where available.

Expedition Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Expedition Therapeutics's valuation, stock price, and market status.

Is Expedition Therapeutics a public or private company?

Expedition Therapeutics is a private company.

What is the current stock price of Expedition Therapeutics?

Expedition Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Expedition Therapeutics worth (valuation)?

Expedition Therapeutics's valuation is estimated at $650.0M based on funding round data.

Can I buy Expedition Therapeutics stock?

Expedition Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Expedition Therapeutics's last funding round?

Expedition Therapeutics's most recent funding round was Series A on October 9, 2025.

Who are the main investors in Expedition Therapeutics?

Key investors in Expedition Therapeutics include Novo Holdings, Sofinnova Investments.

Will Expedition Therapeutics IPO soon?

No public IPO plans have been announced for Expedition Therapeutics.

How can I track Expedition Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Expedition Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range11
Year Founded2024
Last FundingAug 5, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?